Aardvark Therapeutics’ (AARD) Buy Rating Reiterated at BTIG Research

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $9.00 price target on the stock. BTIG Research’s target price would indicate a potential upside of 121.13% from the company’s previous close.

A number of other brokerages have also issued reports on AARD. Oppenheimer lowered their price target on Aardvark Therapeutics from $35.00 to $21.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Raymond James Financial restated a “strong-buy” rating and issued a $47.00 price objective on shares of Aardvark Therapeutics in a report on Monday, January 12th. B. Riley Financial assumed coverage on shares of Aardvark Therapeutics in a research note on Wednesday, January 28th. They set a “buy” rating and a $32.00 target price on the stock. Royal Bank Of Canada cut shares of Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $18.00 to $6.00 in a research note on Monday, March 2nd. Finally, William Blair began coverage on shares of Aardvark Therapeutics in a report on Friday, December 12th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aardvark Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $25.09.

Aardvark Therapeutics Price Performance

AARD stock opened at $4.07 on Tuesday. Aardvark Therapeutics has a 52 week low of $4.01 and a 52 week high of $17.94. The firm has a 50-day simple moving average of $10.82 and a 200-day simple moving average of $11.72. The stock has a market capitalization of $88.60 million and a P/E ratio of -1.92.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.81) earnings per share for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Cresset Asset Management LLC purchased a new position in Aardvark Therapeutics during the third quarter worth about $1,951,000. Wells Fargo & Company MN increased its holdings in shares of Aardvark Therapeutics by 259.5% during the 4th quarter. Wells Fargo & Company MN now owns 14,080 shares of the company’s stock worth $185,000 after buying an additional 10,163 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Aardvark Therapeutics during the 4th quarter worth approximately $181,000. Goldman Sachs Group Inc. purchased a new position in Aardvark Therapeutics in the first quarter worth approximately $153,000. Finally, Bank of America Corp DE grew its position in Aardvark Therapeutics by 72.9% in the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after acquiring an additional 3,369 shares during the period.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (ROR?). ROR? plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective ROR? inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.